CRL vs. LLY: Charles River Laboratories vs. Eli Lilly Stock Comparison

Company Profile

Charles River Laboratories (CRL) and Eli Lilly (LLY) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but CRL is classified in Life Sciences Tools & Services while LLY is classified in Pharmaceuticals.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Charles River Laboratories (CRL) has an aggressive beta of 1.33, indicating higher sensitivity to broad-market moves, while Eli Lilly (LLY) is defensive at 0.40 and tends to be less market-sensitive — they sit on opposite ends of the beta spectrum.

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Eli Lilly (LLY) at 86.02% sits in the top ROE quartile, while Charles River Laboratories (CRL) at 1.27% is closer to the peer norm — stronger capital efficiency for LLY.

Eli Lilly (LLY) at 31.90% converts revenue to bottom-line profit above its industry’s benchmark range, while Charles River Laboratories (CRL) at 1.01% keeps roughly the typical share for its industry.

Both Charles River Laboratories (CRL) at 23.42% and Eli Lilly (LLY) at 53.66% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability Metrics

Growth

Eli Lilly (LLY) at 44.70% is around its peer norm for revenue growth, while Charles River Laboratories (CRL) at -0.85% drops into the bottom quartile, signaling weaker demand or pricing momentum.

Eli Lilly (LLY) at 95.99% sits in the top EPS growth quartile, while Charles River Laboratories (CRL) at -1,555.00% falls below its industry range — a large difference in per-share earnings trajectories.

Growth Metrics

Financial Strength

Both Charles River Laboratories (CRL) at 1.41 and Eli Lilly (LLY) at 1.39 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

Both Charles River Laboratories (CRL) at 0.87 and Eli Lilly (LLY) at 1.23 lean more heavily on debt funding than most peers, landing in the higher-leverage quartile of their industries.

Financial Strength Metrics

Dividends

Charles River Laboratories (CRL) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Eli Lilly (LLY) reports a yield of 0.49%, ranking against industry peers normally.

Charles River Laboratories (CRL) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Eli Lilly (LLY) reports a payout of 21.71%, ranking against industry peers normally.

Dividend Metrics

Valuation

Both look expensive on trailing earnings: Eli Lilly (LLY) at 43.95 sits in the richer P/E ratio quartile, and Charles River Laboratories (CRL) at 366.87 is richer still, above its industry range.

On P/S ratio, both Charles River Laboratories (CRL) at 4.07 and Eli Lilly (LLY) at 13.95 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

Charles River Laboratories (CRL) at 5.01 sits near its industry’s typical P/B ratio, while Eli Lilly (LLY) at 29.96 prices above its benchmark range — LLY looks rich relative to book.

Valuation Metrics